Stay updated on Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange Detected- The page shows additions and deletions of date strings (e.g., 2025-12-23, 2025-12-04, 2025-12 and 2025-11-13, 2025-11-06, 2025-11), which appear to be update timestamps rather than alterations to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoChange DetectedAdded a new Locations section with an expanded list of study sites (Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan, Minnesota, Missouri, New Jersey, Oregon, Pennsylvania, Tennessee, Texas, Virginia, Ontario, Quebec) and updated to Revision: v3.3.3; removed the prior per-state location subsections such as 'Arizona Locations' and 'California Locations'.SummaryDifference0.6%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedRevision: v3.3.2 updated from v3.3.1; no substantive study information is affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check44 days agoChange DetectedPubMed auto-fill clarification and a new Revision: v3.3.1 have been added to the Publications section. The previous PubMed auto-fill description and Revision: v3.2.0 text were removed.SummaryDifference0.0%

- Check51 days agoChange DetectedAdded a new trial site in Tainan, Taiwan (704) on 2025-11-13, with related updates on 2025-11-06 and 2025-11.SummaryDifference0.2%

- Check59 days agoChange DetectedAdded a new NEJM publication entry for MARIPOSA: Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC (N Engl J Med, Oct 30, 2025; DOI: 10.1056/NEJMoa2503001; Epub Sep 7, 2025). Removed the previous 'Online ahead of print' listing for the same article (Sept 7, 2025).SummaryDifference0.0%

Stay in the know with updates to Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.